KURE

KraneShares MSCI All China Health Care Index UCITS ETF

Download KURE Presentation

Download Fact Sheet

Investment Strategy:

KURE seeks to measure the performance of MSCI China All Shares Health Care 10/40 Index. The Index is a free float adjusted market capitalization weighted index designed to track the equity market performance of Chinese companies engaged in the health care sector. The securities in the Index include all types of publicly issued shares of Chinese issuers, which are listed in Mainland China, Hong Kong and the United States. Issuers eligible for inclusion must be classified under the Global Industry Classification Standard (GICS) as engaged in the healthcare sector. The issuers included in the Underlying Index may include small-cap, mid-cap and large-cap companies.

China Health Care Sector Highlights:

  • China is one of the fastest growing major healthcare markets in the world with a ten-year compound annual growth rate of 13%, compared to just 3% in the United States and 2% in Japan1.
  • China is the second largest healthcare market globally with total healthcare expenditures reaching $1.02 trillion in 2019, an increase of roughly 87% over the last 5 years2.
  • There is still opportunity for considerable growth in China’s healthcare market with per capita health spending at just $441, compared to an average of over $5,400 for the world’s top eight healthcare markets3.
  • China’s aging population, rising incomes and increasing urbanization may provide a sustained catalyst for growth in China’s healthcare sector.

KURE features:

  • Exposure to Chinese companies listed in the Mainland, Hong Kong and United States that are involved in the healthcare industry. Specifically: patent and generic pharmaceuticals, hospital administration, biotechnology, medical equipment production, healthcare IT, and traditional Chinese medicine.
  • Exposure to companies that benefit from China’s growing middle class and aging population.
  • Access to leading Chinese pharmaceutical companies which have been recipients of favorable policy and market conditions for research and development and the invention of new medicines and devices.

1.) Major healthcare markets defined as top five global markets by the World Health Organization. Data from the World Health Organization as of 31/Dec/2017, last updated on 7/Apr/2020. Retrieved 31/Dec/2020.

2.) Statista, Health expenditure in China 2000-2019”, Published by Lai Lin Thomala, Dec 17, 2020, Retrieved 31/Dec/2020.

3.) Data from the World Health Organization, last updated on 7/Apr/2020. Retrieved 31/Dec/2020.

Listings

Data as of 21/Sep/2021
Exchange Ticker Currency Listing Date SEDOL ISIN
London Stock Exchange KURE LN USD 14/Jan/2021 BMZ4LD0 IE00BL6K0S82

Daily Performance

Data as of 21/Sep/2021
NAV
Net Asset Value$23.28 
Daily Change 0.00%

Performance History

Cumulative %
Data as of: 31/Aug/2021
Fund NAV Index
1 Month-9.02%
3 Month-18.49%
6 Month-10.12%
Since Inception-10.44%
Cumulative %
Data as of quarter end: 30/Jun/2021
Fund NAV Index
Since Inception13.56%

The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted.

Top 10 Holdings

Data as of
Full Holdings .CSV
RankCompany Name% of Net AssetsTickerShares HeldMarket Value($)
1
WUXI BIOLOGICS CAYMAN INC
9.38%2269 HK42,000655,260
2
SHENZHEN MINDR-A
5.53%300760 C26,900386,117
3
WUXI APPTEC CO LTD-A
4.85%603259 C114,420338,776
4
BEIGENE LTD-ADR
4.48%BGNE805312,751
5
JIANGSU HENGRU-A
3.76%600276 C136,280262,582
6
AIER EYE HSPTL-A
3.53%300015 C230,694246,332
7
CHONGQING ZHIF-A
2.95%300122 C28,400205,801
8
CSPC PHARMACEUTI
2.9%1093 HK166,000202,284
9
INNOVENT BIOLOGICS INC
2.77%1801 HK22,000193,227
10
ZHANGZHOU PIEN-A
2.6%600436 C13,400181,345

Holdings are subject to change.